Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant



Khan, Ahsan A, Hardy, Lewis J, Shantsila, Eduard ORCID: 0000-0002-2429-6980, Lau, Yee C, Philippou, Helen and Lip, Gregory YH ORCID: 0000-0002-7566-1626
(2021) Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. THROMBOSIS RESEARCH, 197. pp. 69-76.

[thumbnail of Observations on clot properties in atrial fibrillation- Relation to renal function and choice of anticoagulant - Thromb Res 2021.docx] Text
Observations on clot properties in atrial fibrillation- Relation to renal function and choice of anticoagulant - Thromb Res 2021.docx - Author Accepted Manuscript

Download (382kB)

Abstract

<h4>Introduction</h4>Atrial fibrillation (AF) is associated with increased risk of stroke and thromboembolism. Patients with AF have a higher incidence of renal impairment, which may influence the risks of systemic thromboembolism or bleeding. We determined how different oral anticoagulants affect plasma clot properties and whether progressive renal dysfunction affects plasma clot properties in patients on warfarin.<h4>Materials and methods</h4>We studied 257 patients with AF receiving oral anticoagulants. Furthermore, we recruited 192 separate patients with AF on warfarin and divided them in 4 groups based on estimated glomerular filtration rate (eGFR). Platelet poor plasma was prepared and clot formation and fibrinolysis was monitored kinetically up to 1 h.<h4>Results</h4>Rate of clot formation was significantly slower with dabigatran and rivaroxaban. Time between 50% clotting and 50% lysis was prolonged in patients receiving warfarin compared to NOACs. Time to 50% lysis from maximum absorbance was significantly shorter in patients receiving rivaroxaban. Time between 50% clotting and 50% lysis became significantly prolonged with worsening eGFR. Time to 50% lysis from maximum absorbance was prolonged as renal function worsened.<h4>Conclusions</h4>Compared to warfarin, NOACs differently modulate coagulation and fibrinolysis under ex vivo conditions. Worsening renal function in AF patients on warfarin prolongs fibrinolysis, potentially increasing the risk of thrombosis.

Item Type: Article
Uncontrolled Keywords: Atrial fibrillation, Coagulation, Fibrinolysis, Chronic kidney disease, Anticoagulants
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Faculty of Health and Life Sciences > Institute of Population Health
Depositing User: Symplectic Admin
Date Deposited: 08 Aug 2022 07:37
Last Modified: 18 Jan 2023 20:53
DOI: 10.1016/j.thromres.2020.10.039
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3160559